Menu
1 min read · estimated
APPROVED USE
What FDA approved
Lower-strength 50 mg and 100 mg capsules for labeled Philadelphia chromosome-positive CML uses, including chronic-phase disease in patients aged one year or older who are newly diagnosed or resistant or intolerant to earlier therapy.
LAMPGEN ANALYSIS
Why it matters
The added capsule strengths support dosing across a wider range of patients with CML.
What research teams should watch
Track formulation and capsule strength in the medication record, especially for pediatric dose adjustments.
PRIMARY RECORDS